MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1378/chest.121.1.55

Медицинская библиотека · Chest · 2002

Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis.

Moss Richard B

Клиническое исследованиеСтатьяРандомизированное исследованиеПеревод пока не подготовлен

Аннотация

STUDY

OBJECTIVE

To determine the effect of long-term suppression of Pseudomonas aeruginosa on lung function and other clinical end points in adolescent patients with cystic fibrosis (CF).

DESIGN

Two identical, randomized, placebo-controlled trials followed by three open-label follow-on trials.

SETTING

Sixty-nine CF study centers in the United States.

INTERVENTIONS: Active drug consisting of a 300-mg tobramycin solution for inhalation (TSI).

PATIENTS: One hundred twenty-eight adolescent CF patients (aged 13 to 17 years) with P aeruginosa and mild-to-moderate lung disease (FEV(1) percent predicted > or = 25% and < or = 75%).

MEASUREMENTS: Pulmonary function, P aeruginosa colony forming unit density, incidence of hospitalization and IV antibiotic use, weight gain, and aminoglycoside toxicity were monitored.

RESULTS

At the end of the first three 28-day cycles of TSI treatment, patients originally randomized to TSI and placebo treatments exhibited improvements in FEV(1) percent predicted of 13.5% and 9.4%, respectively. FEV(1) percent predicted was maintained above the value at initiation of TSI treatment in both groups. At the end of the last "on-drug" period (92 weeks), patients originally randomized to TSI and placebo treatments showed improvements of 14.3% and 1.8%, respectively. Improvement in pulmonary function was significantly correlated with reduction in P aeruginosa colony forming unit density (p = 0.0001). The average number of hospitalizations and IV antibiotic courses did not increase over time. TSI treatment was associated with increased weight gain and body mass index. P aeruginosa susceptibility to tobramycin decreased slightly over time, but this was not correlated with clinical response.

CONCLUSIONS

TSI treatment improved pulmonary function and weight gain in adolescent patients with CF over a 2-year period of long-term, intermittent use.

Для цитирования: Moss Richard B. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis.. Chest. 2002. DOI: 10.1378/chest.121.1.55.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.